Background/Aims: Notch signaling pathway regulates cancer cell growth. RBPJ is a key transcription factor downstream of Notch receptor activation, whereas the role of RBPJ in carcinogenesis of prostate cancer is ill-defined. Methods: Here, we evaluated the effects of RBPJ inhibition on the growth of prostate cancer cells. We knocked down RBPJ in prostate cancer cells by a short hairpin interfering RNA (shRNA). We measured cell growth by an MTT assay. We analyzed the levels of cell-cycle-associated proteins by Western blot. Results: We found that shRNA for RBPJ efficiently inhibited RBPJ expression in prostate cancer cells, resulting in a significant decrease in the cell growth. Further, RBPJ-mediated cell-growth inhibition appeared to be resulting from alteration of cell-cycle inhibitors p21 and p27, cellcycle activators CDK2, CDK4 and CyclinD1, and apoptosis-suppressor Bcl-2. Conclusion: Our data suggest that shRNA intervention of RBPJ expression could be a promising therapeutic approach for treating human prostate cancer.
Introduction
Prostate cancer is one of the most common cancers in aged men [1] [2] [3] [4] . Although our understanding and treatment of prostate cancer have significantly improved in the past years, the molecular regulation of the growth of prostate cancer cells is not yet clarified [1] [2] [3] [4] [5] [6] [7] [8] [9] .
The Notch pathway has been shown to upregulate in many types of cancer, which suggests a role of this pathway in the tumorigenesis. Notch signaling pathway is highly conserved in evolution and plays important roles during development, in which Notch signals regulate various physiological processes, including maintenance of stem cells, cell fate decisions, proliferation, differentiation and apoptosis [10, 11] .
Recombination signal-binding protein Jκ (RBPJ) is a DNA-binding protein from CSL family of transcription factors [12] . RBPJ recognizes a consensus sequence C(T)GTGGGAA on RBPJ-binding sites from a number of factors [12] . Importantly, RBPJ also mediates signals from Notch receptors [13] [14] [15] . In the absence of Notch signals, RBPJ is associated with some corepressors that repress Notch transcription. After ligand binding, Notch signaling is initiated by γ-secretase-mediated proteolytic cleavage and liberation of the Notch intracellular domain (NICD). NICD subsequently translocates into the nucleus to displace corepressors from RBPJ, which allows for the recruitment of coactivators to bind with RBPJ to thereby induce the activation of target genes like hairy and enhancer of split 1 (Hes-1), cyclin-dependent kinase 2 (CDK2), B-cell CLL/lymphoma 2 (Bcl-2), ubiquitin ligase complex SCFSKP2 (SKP2), p21 and p27 [13, 14, [16] [17] [18] [19] [20] [21] .
Although RBPJ has been shown to play a role in the tumorigenesis of some cancers, and inhibition of RBPJ significantly may impair or promote cancer growth depending on cancer cell type, the knockdown of RBPJ by RNA interference (RNAi) in prostate cancer cells has not been studies.
Here, we evaluated the regulation of prostate cancer cells by RBPJ depletion. We used a short hairpin RNA (shRNA) to efficiently inhibit RBPJ expression in prostate cancer cells, which significantly decreased the cancer cell growth. Further analyses showed that RBPJ inhibition altered the levels of its downstream targets, including p21, p27, CDK2, CDK4, CyclcinD1 and Bcl-2, to suppress the growth of the prostate cancer cells.
Materials and Methods
Cell culture HEK293T cells and human prostate cancer cell lines PC3 and DU145 were purchased from ATCC (American Type Culture Collection, Manassas, VA, USA), and have been described before [22, 23] . These two cell lines were all cultured in in Dulbecco's modified Eagle's medium (DMEM, Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Invitrogen) and 1% penicillin and streptomycin in a 5% CO 2 humidified cell-culture incubator at 37°C.
RT-qPCR
Total RNA was extracted from cultured cells with RNeasy kit (Qiagen, Hilden, Germany). cDNA was synthesized from 1µg of total RNA using a reverse transcription kit (Qiagen) and purified with the QIAquick PCR Purification Kit (Qiagen). Quantitative PCR (RT-qPCR) was performed in duplicates with QuantiTect SYBR Green PCR Kit (Qiagen) with a LightCycler 1.5 Real-time PCR machine (Roche, Indianapolis, IN, USA). Primers were designed to amplify the fragments cross exons are: RBPJ (132 bp), forward primer 5'-CGCATTATTGGATGCAGATG-3' and reverse primer 5'-CAGGAAGCGCCATCATTTAT-3'; α-tubulin (125 bp), forward primer 5'-CCAAGCTGGAGTTCTCTA-3', reverse primer 5'-CAGAGTGCTCCAGG-3'. Values of RBPJ were first normalized against GAPDH and then compared with controls.
Preparation of RBPJ-shRNAs
The coding sequence of RBPJ was amplified with forward primer 5'-GGAAGATGGCGCCTGTTGTGACAG-3' and reverse primer 5'-GTTATCTCGAGTCAAGCGTAGTCTGGGACGGTATGGGTAGGACACCACGGTTGCTGTG-3'. The underlined sequence represents a HA tag. The amplicons were digested with Xhol and BamHI and subcloned into a pcDNA3.1 expression vector (Invitrogen), resulting in a construct named pcDNA-RBPJ. Short hairpin interfering RNAs (shRNAs) targeting RBPJ mRNA (NM_005349.3) were designed, according to the Dharmacon siDESIGN Center database. Five shRNAs that target the RBPJ coding region were selected based on ranking criteria of Reynolds [24] . All the shRNAs were cloned into pLKO.1 vector (Sigma-Aldrich, St. Louis, MO, USA), with pLKO.1 itself (with a scrambled shRNA) used as control.
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Transfection HEK293T cells were seeded in six-well plates in complete media one day prior to transfection. To generate the recombinant, the HEK293T packaging cells were transfected with 5-8 µg pVSV-G (Clontech, Mountain View, CA) and 15 µg of recombinant vectors using Lipofectamine-2000 (Invitrogen), according to the manufacturer's instruction. The transfected cells were then harvested and whole cell lysates were extracted for Western blot using an anti-RBPJ antibody (Abcam, Cambridge, MA, USA).
Generation of RBPJ knockdown stable clones of prostate cancer cells
To generate RBPJ-shRNA lentiviral particles, HEK293T cells were seeded in a 100 mm dish at 50,000 cells/cm 2 and co-transfected with 10 µg of RBPJ-shRNA and 5 µg each of packaging plasmids (REV, pMDL and VSV-G) using Lipofectamine-2000 (Invitrogen). The supernatant containing lentiviral particles was collected 48 hours after transfection and filtered through a 0.45 µm syringe filter. Target prostate cancer cells were seeded in 100 mm plates at 15,000 cells/cm 2 one day prior to lentiviral infection. The lentiviral particles were added along with 10 µg/ml polybrene (Sigma-Aldrich) to the cell culture for 24 hours. Then the cells were washed twice with complete media and cultured in the presence of puromycin to select the transduced cells.
Western blot analyses
Proteins were extracted in a solution of RIPA and Protease Inhibitor Cocktail (Thermo Scientific, Waltham, MA, USA) from HEK293T cells or prostate cancer cells and subjected to SDS-PAGE. Quantification of total protein was carried out using BCA kit (Sigma-Aldrich). The proteins (100 µg) were subjected to 12% SDS-PAGE. Separated proteins were electrophoretically transferred to a nitrocellulose membrane (BioRad, Hercules, CA, USA) and immune-blotted with monoclonal mouse anti-human RBPJ (Abcam), polyclonal rabbit anti-human p21 (Abcam), polyclonal rabbit anti-human p27 (Abcam), polyclonal rabbit anti-human Hes1 (Abcam), polyclonal rabbit anti-human SKP2 (Cell Signaling, San Jose, CA, USA) or polyclonal rabbit anti-human α-tubulin (Cell Signaling) antibodies. GAPDH was used as a protein loading control. Secondary antibody is HRP-conjugated anti-rabbit (Jackson Labs, Bar Harbor, ME, USA). Images shown in the figure were representative from 5 repeats. Densitometry of Western blots was quantified with NIH ImageJ software.
Cell growth assay
A diphenyltetrazolium bromide (MTT) assay was performed to determine cell growth. Five thousand cells per well were seeded in a 96-well plate and grown for 24, 48 and 72 hours. Then the media were removed and washed with PBS, after which 5g/l of thiazolyl tetrazolium (Amersco, Indianapolis, IN, USA) was added to each well. Four hours later, MTT was removed and 150µl of dimethyl sulfoxide (Sigma-Aldrich, St. Louis, MO, USA) was added. The viability of the cells was calculated from the absorption at 570/630 nm with an enzyme-linked immunosorbent assay reader.
Cell cycle analyses
Cell pellets were resuspended in a cold solution containing 100 µg/ml propidium iodide (SigmaAldrich), 0.1% Tri-sodium citrate, and 10% RNaseA (1 mg/ml) and then incubated at 37°C for 30min. Cell cycles were then analyzed by flow cytometry.
Statistics
All statistical analyses were carried out using the SPSS 19.0 statistical software package. All data were statistically analyzed using one-way ANOVA with a Bonferoni Correction. All values are depicted as mean ± standard deviation from 5 individuals and are considered significant if p < 0.05.
Results

RBPJ expression was effectively inhibited by shRNA constructs
Multiple shRNA constructs were generated and then co-transfected with pcDNA-RBPJ into HEK293T cells to determine their potentials of silencing RBPJ expression. RBPJ protein levels in the transfected cells were determined by Western blot. All 4 shRNAs resulted in and by quantification (B) . Scr, cells transfected with pLKO.1 vector with a scrambled shRNA. shRBPJ-a to shRBPJ-d, different shRNA constructs designed to target RBPJ based on mRNA sequence. GAPDH was a protein loading control. *p<0.05. n=5. Statistics: one-way ANOVA with a Bonferoni Correction.
Fig. 2. Inhibition of RBPJ by lenti-shRBPJ-c in stably transduced prostate cancer cells. (A-C)
Two prostate cancer cells were infected with RBPJ-shRNA and scr-carrying lentivirus to generate stable clones which were then cultured in media for 72 hours before they were harvested. RBPJ levels were significantly reduced in either stably transduced prostate cancer cell lines, by RT-qPCR (A), and by Western blot shown with representative images (B) and with quantification (C). GAPDH was a protein loading control. *p<0.05. n=5. Statistics: one-way ANOVA with a Bonferoni Correction.
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infected with RBPJ-shRNA and pLKO.1 lentivirus carrying scrambled sequence (scr) to generate stable clones which were then cultured in media for 72 hours before they were harvested. We found that RBPJ levels were significantly reduced in either stably transduced prostate cancer cell lines, by RT-qPCR ( Fig. 2A) , and by Western blot shown with representative images (Fig. 2B ) and with quantification (Fig. 2C ). These data suggest that shRBPJ inhibited RBPJ transcription, and reduced the RBPJ protein production in prostate cancer cells.
Inhibition of RBPJ suppressed growth of prostate cancer cells
In order to figure out whether inhibition of RBPJ may affect the growth of prostate cancer cells, we analyzed cell growth in a MTT assay. Significant reduced cell growth by RBPJ inhibition was detected as early as 48 hours after seeding, compared with controls, in both lines (Fig. 3A) . We then analyzed these cancer cells in a cell cycle phase assay at 72 hours after seeding, and we found that the percentage of S-phase proliferating cells in RBPJdepleted prostate cancer cells significantly decreased, while the percentage of G0/G1-phase cells in RBPJ-depleted prostate cancer cells significantly increased, compared to the control scr-transfected cells (Fig. 3B) . These results suggest that inhibition of RBPJ suppressed growth of prostate cancer cells, possibly through inhibiting cell proliferation.
RBPJ-depletion inhibited cell proliferation by suppressing S-phase transition
To understand the mechanism underlying the reduced cell growth by RBP depletion, we examined the expression of downstream targets of RBPJ by Western blot. CDK2 and CDK4 are catalytic subunits of the cyclin-dependent kinase complex, and their activities are restricted to the G1-S phase of the cell cycle for inducing G1-S transition. CyclinD1 is a cellcycle activator to form complexes with CDK2 and CDK4 to induce G1-S transition. The cellcycle inhibitor p21 inhibits formation of cyclin-CDK2 complexes. The p27 directly inhibits CDK4, resulting in cell arrest in the G1 phase of the cell cycle [13, 14, [16] [17] [18] [19] [20] [21] [25] [26] [27] [28] . We found that RBPJ-depleted prostate cancer cells exhibited a reduction in the levels of CDK2, CDK4, CyclinD1 and apoptosis-suppressor Bcl-2, but an increase in the levels of p21 and p27, compared to control cells (Fig. 4) . These results further suggest that RBPJ-depletion inhibited cell proliferation by suppressing S-phase transition.
Discussion
Inhibition of Notch pathway has been shown to suppress tumorigenesis of prostate cancers . Moreover, RBPJ acts downstream of the Notch pathway and has been shown to be essential for a functional activated Notch signaling [13, 14, [16] [17] [18] [19] [20] [21] . Therefore, here we studied the specific role of RBPJ in the Notch pathway, and evaluated its effect as a potential therapeutic target for prostate cancer.
We used a lentivirus-mediated shRNA delivery method to stably suppress RBPJ gene expression. Both short interfering RNAs (siRNAs) and shRNAs are the most frequently applied methods to specifically and efficiently silence genes at the mRNA level [50, 51] . Delivery of siRNAs or shRNAs by plasmid transfection to target cells suffers from low and variable transfection efficiency and only suppresses gene expression transiently [50, 51] . On the contrary, lentiviral vectors are more efficient, and conduct stable gene delivery [50, 51] . The lentiviral vector pLKO.1 is able to integrate into the host genome that allows for the stable expression of shRNA.
Our results showed that the downregulation of RBPJ expression resulted in a significant reduction of cell growth in transduced prostate cancer cells, confirmed by cell cycle analyses showing that knockdown of RBPJ decreased S-phase proliferating cells. Moreover, we found that knockdown of RBPJ suppressed the expression of its target genes CDK2, CDK4, CyclinD1, and apoptosis-suppressor Bcl-2, but increased others like p21 and p27. The decreases in Bcl-2 may be feedback from alternation of CDKs and Cyclins. Given the roles of these genes in cell cycle progression, our results suggest that the knockdown of RBPJ inhibits prostate cancer cell proliferation by inducing cell-cycle arrest at G1 phase through inhibiting the G1-S transition, as well as by promoting cell apoptosis.
Since we examined two prostate cancer cell lines and got same results, our results should not be limited to an individual cell line. In another word, our results are unlikely to be cell-line specific. Since Notch signaling pathway has been shown to play essential roles in many cancers other than prostate cancer, here the inhibitory effect of RBPJ-depletion on Fig. 4 . RBPJ-depletion inhibited cell proliferation by suppressing S-phase transition. The levels of downstream targets of RBPJ were examined by Western blot, showing that RBPJ-depleted prostate cancer cells exhibited a reduction in the levels of CDK2, CDK4 and CyclinD1, but an increase in the levels of p21, p27 and Bcl-2, compared to control cells. GAP-DH was a protein loading control.
